Table 2.
Absolute prevalence differences of enrichment comorbidities in subgroups of patients with thyroid diseases on the private data set.
| ICD-10a code | Enrichment comorbidity | Crude prevalence (95% CI) | Absolute prevalence difference, value (95% CI) | |
| Male – Female | TCb – BTDc | |||
| A49 | Bacterial infection | 2.7 (2.5 to 3.0) | N/Ad | –2.6 (–3.0 to –2.2) |
| B66 | Fluke infections | 3.4 (3.1 to 3.6) | 5.1 (4.5 to 5.7) | –3.0 (–3.5 to –2.5) |
| C11 | Nasopharyngeal carcinoma | 1.7 (1.5 to 1.9) | 2.2 (1.8 to 2.6) | –1.7 (–2.0 to –1.4) |
| C22 | Malignant neoplasm of the liver and intrahepatic bile ducts | 1.7 (1.5 to 1.9) | 1.8 (1.4 to 2.2) | –1.8 (–2.0 to –1.6) |
| C34 | Bronchial and lung cancer | 7.8 (7.4 to 8.1) | 3.7 (2.9 to 4.5) | –7.5 (–8.1 to –6.9) |
| C50 | Malignant neoplasm of the breast | 2.4 (2.2 to 2.6) | –3.9 (–4.3 to –3.5) | –2.5 (–2.8 to –2.2) |
| C77 | Secondary lymph node carcinoma | 9.2 (8.8 to 9.7) | 4.0 (3.1 to 4.9) | 31.9 (29.0 to 34.8) |
| C78 | Secondary malignant neoplasm of the respiratory and digestive organs | 6.4 (6.1 to 6.8) | N/A | –3.0 (–4.1 to –1.9) |
| C79 | Secondary malignant neoplasm | 5.3 (5.0 to 5.6) | 2.9 (2.2 to 3.6) | –3.2 (–4.1 to –2.3) |
| C90 | Multiple myeloma and malignant plasma cell neoplasms | 1.7 (1.5 to 1.9) | 1.9 (1.5 to 2.3) | –1.8 (–2.0 to –1.6) |
| D18 | Hemangioma and lymphangioma | 3.1 (2.8 to 3.3) | N/A | –2.1 (–2.8 to –1.4) |
| D25 | Leiomyoma of the uterus | 3.3 (3.0 to 3.5) | –5.4 (–5.8 to –5.0) | –2.9 (–3.4 to –2.4) |
| D64 | Anemias | 8.5 (8.1 to 8.9) | N/A | –6.9 (–7.8 to –6.0) |
| E11 | Diabetes mellitus | 16.8 (16.3 to 17.4) | 7.2 (6.1 to 8.3) | –14.6 (–15.8 to –13.4) |
| E27 | Disorders of the adrenal gland | 3.3 (3.1 to 3.6) | 2.2 (1.6 to 2.8) | –3.4 (–3.8 to –3.0) |
| E55 | Vitamin D deficiency | 4.8 (4.5 to 5.2) | N/A | –5.0 (–5.4 to –4.6) |
| E77 | Disorders of glycoprotein metabolism | 4.4 (4.1 to 4.7) | N/A | –3.3 (–4.0 to –2.6) |
| E78 | Disorders of lipoprotein metabolism | 15.3 (14.8 to 15.8) | N/A | –12.5 (–13.7 to –11.3) |
| E79 | Disorders of purine and pyrimidine metabolism | 5.4 (5.1 to 5.7) | 3.8 (3.1 to 4.5) | –3.1 (–4.1 to –2.1) |
| E83 | Disorders of mineral metabolism | 1.6 (1.4 to 1.8) | N/A | 2.5 (1.3 to 3.7) |
| E87 | Disorders of fluid balance | 6.9 (6.6 to 7.3) | N/A | –3.5 (–4.7 to –2.3) |
| G31 | Degenerative diseases of the nervous system | 2.3 (2.0 to 2.5) | 1.1 (0.6 to 1.6) | –2.4 (–2.6 to –2.2) |
| G47 | Sleep disorders | 2.6 (2.4 to 2.9) | N/A | –2.7 (–3.0 to –2.4) |
| G63 | Polyneuropathy diseases | 3.3 (3.0 to 3.5) | N/A | –3.4 (–3.7 to –3.1) |
| I10 | Hypertension | 35.1 (34.5 to 35.8) | N/A | –25.2 (–27.2 to –23.2) |
| I11 | Hypertensive heart disease | 9.3 (8.9 to 9.7) | 4.2 (3.3 to 5.1) | –9.3 (–9.9 to –8.7) |
| I20 | Angina pectoris | 4.2 (3.9 to 4.5) | 3.5 (2.9 to 4.1) | –4.4 (–4.8 to –4.0) |
| I25 | Ischemic heart disease | 14.9 (14.4 to 15.5) | 8.1 (7.0 to 9.2) | –14.6 (–15.5 to –13.7) |
| I48 | Atrial fibrillation and flutter | 3.1 (2.9 to 3.4) | 1.5 (1.0 to 2.0) | –3.2 (–3.5 to –2.9) |
| I49 | Cardiac arrhythmias | 5.3 (5.0 to 5.6) | N/A | –5.3 (–5.8 to –4.8) |
| I50 | Heart failure | 7.4 (7.0 to 7.7) | 4.6 (3.8 to 5.4) | –7.8 (–8.2 to –7.4) |
| I63 | Cerebral infarction | 9.3 (8.9 to 9.7) | 4.2 (3.3 to 5.1) | –9.8 (–10.3 to –9.3) |
| I65 | Anterior cerebral artery stenosis and occlusion | 3.0 (2.7 to 3.2) | N/A | –3.2 (–3.5 to –2.9) |
| I67 | Cerebrovascular diseases | 4.2 (3.9 to 4.5) | N/A | –4.3 (–4.7 to –3.9) |
| I69 | Sequelae of cerebrovascular disease | 2.9 (2.7 to 3.1) | 2.3 (1.8 to 2.8) | –2.8 (–3.2 to –2.4) |
| I70 | Atherosclerosis | 16.1 (15.5 to 16.6) | N/A | –15.3 (–16.2 to –14.4) |
| I79 | Disorders of arteries, arterioles, and capillaries | 3.6 (3.3 to 3.9) | N/A | –3.9 (–4.2 to –3.6) |
| J15 | Bacterial pneumonia | 11.6 (11.1 to 12.0) | N/A | –11.8 (–12.4 to –11.2) |
| J18 | Pneumonia | 9.2 (8.8 to 9.7) | N/A | –5.8 (–7.0 to –4.6) |
| J32 | Chronic sinusitis | 3.0 (2.8 to 3.3) | 1.6 (1.1 to 2.1) | –2.4 (–3.0 to –1.8) |
| J43 | Emphysema | 4.1 (3.8 to 4.3) | 5.1 (4.4 to 5.8) | –2.7 (–3.5 to –1.9) |
| J44 | Chronic obstructive pulmonary disease | 1.9 (1.7 to 2.1) | 3.2 (2.7 to 3.7) | –2.1 (–2.3 to –1.9) |
| J94 | Pleural conditions | 4.1 (3.8 to 4.4) | N/A | –3.9 (–4.4 to –3.4) |
| K29 | Gastritis and duodenitis | 13.5 (13.0 to 14.0) | N/A | –13.4 (–14.2 to –12.6) |
| K31 | Diseases of the stomach and duodenum | 2.9 (2.7 to 3.1) | N/A | –3.0 (–3.3 to –2.7) |
| K63 | Diseases of intestine | 2.6 (2.3 to 2.8) | N/A | –2.7 (–2.9 to –2.5) |
| K74 | Fibrosis and cirrhosis of the liver | 2.3 (2.1 to 2.5) | 1.7 (1.2 to 2.2) | –1.8 (–2.3 to –1.3) |
| K76 | Liver disease | 22.0 (21.4 to 22.6) | N/A | –17.4 (–18.9 to –15.9) |
| K80 | Cholelithiasis | 9.2 (8.7 to 9.6) | N/A | –7.7 (–8.6 to –6.8) |
| K82 | Diseases of the gallbladder | 3.3 (3.1 to 3.6) | N/A | –1.7 (–2.5 to –0.9) |
| M10 | Gout | 2.4 (2.2 to 2.6) | 4.6 (4.1 to 5.1) | –2.2 (–2.6 to –1.8) |
| M35 | Systemic involvement of connective tissue | 2.0 (1.8 to 2.2) | –2.5 (–2.8 to –2.2) | –2.0 (–2.3 to –1.7) |
| M48 | Spondylopathies | 4.8 (4.5 to 5.1) | –2.1 (–2.7 to –1.5) | –4.8 (–5.3 to –4.3) |
| M50 | Cervical disc disorders | 2.4 (2.2 to 2.6) | –1.3 (–1.7 to –0.9) | –2.4 (–2.7 to –2.1) |
| M51 | Intervertebral disc disorders | 4.0 (3.7 to 4.3) | N/A | –4.0 (–4.4 to –3.6) |
| M80 | Osteoporosis with pathological fracture | 1.9 (1.7 to 2.1) | –1.6 (–2.0 to –1.2) | –1.9 (–2.2 to –1.6) |
| M81 | Osteoporosis without pathological fracture | 7.1 (6.7 to 7.4) | –4.2 (–4.9 to –3.5) | –7.2 (–7.7 to –6.7) |
| N04 | Nephrotic syndrome | 3.0 (2.8 to 3.3) | 3.1 (2.5 to 3.7) | –3.2 (–3.5 to –2.9) |
| N08 | Glomerular disorders | 4.1 (3.8 to 4.3) | N/A | –4.2 (–4.6 to –3.8) |
| N18 | Chronic renal failure | 5.5 (5.1 to 5.8) | 4.5 (3.8 to 5.2) | –5.6 (–6.0 to –5.2) |
| N20 | Calculus of the kidney and ureter | 5.4 (5.0 to 5.7) | 3.0 (2.3 to 3.7) | –4.2 (–5.0 to –3.4) |
| N28 | Disorders of the kidney and ureter | 12.1 (11.6 to 12.6) | 6.0 (5.0 to 7.0) | –11.2 (–12.1 to –10.3) |
| N39 | Disorders of the urinary system | 3.0 (2.8 to 3.3) | –1.5 (–2.0 to –1.0) | –3.2 (–3.5 to –2.9) |
| N40 | Hyperplasia of the prostate | 7.5 (7.1 to 7.9) | 19.2 (18.3 to 20.1) | –7.7 (–8.2 to –7.2) |
| N60 | Benign mammary dysplasia | 1.5 (1.3 to 1.7) | –2.5 (–2.8 to –2.2) | N/A |
aICD-10: International Classification of Diseases, 10th Revision.
bTC: thyroid cancer.
cBTD: benign thyroid disease.
dNot applicable, as the comorbidity was not enriched in this subgroup.